drugset
drugset / Trial / NCT03492398

A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis

NCT03492398 ↗

Phase 1 Completed 56 enrolled Shaperon
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in healthy male volunteers as a possible treatment option for atopic dermatitis

Timeline

Start
2018-01-29
Primary completion
2019-03-21
Completion
2019-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TAURODEOXYCHOLIC ACID Small molecule 0.05 % Other
Subject TAURODEOXYCHOLIC ACID Small molecule 0.1 % Other
Subject TAURODEOXYCHOLIC ACID Small molecule 0.3 % Other
Subject TAURODEOXYCHOLIC ACID Small molecule 0.5 % Other

Indications

atopic eczema